RNAi Therapeutics
•24 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (24)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
RNAi therapeutics are part of Lilly's genetic medicine push.
|
$1.00T |
$1065.49
+0.55%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
C5 siRNA program represents RNA interference therapeutics in Regeneron’s genetic medicines portfolio.
|
$80.12B |
$763.21
+0.97%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$57.20B |
$429.07
-1.67%
|
|
RNA
Avidity Biosciences, Inc.
RNA interference (siRNA) payloads are part of the therapeutic approach described (AOC delivering RNA-based payloads).
|
$9.08B |
$71.06
+0.72%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$5.59B |
$44.02
+8.83%
|
|
CRSP
CRISPR Therapeutics AG
SRSD107 is an RNA interference therapeutic, aligning with the RNAi Therapeutics category.
|
$4.57B |
$50.20
-0.05%
|
|
APLS
Apellis Pharmaceuticals, Inc.
APLJ? APL-3007 is an siRNA therapeutic targeting FcRn, placing the program under the RNAi Therapeutics theme.
|
$2.48B |
$20.12
+2.63%
|
|
SRPT
Sarepta Therapeutics, Inc.
siRNA platform (TRiM) with Arrowhead collaboration positions Sarepta in RNA interference therapeutics.
|
$1.73B |
$18.71
+5.79%
|
|
QURE
uniQure N.V.
miQURE silencing technology enables RNA interference-based therapeutics, placing the company in the RNAi therapeutics modality.
|
$1.53B |
$26.98
-2.98%
|
|
AGIO
Agios Pharmaceuticals, Inc.
AG-236 is an siRNA (RNAi) therapeutic in preclinical development, fitting RNAi therapeutics as a major modality in Agios's pipeline.
|
$1.47B |
$25.77
+2.08%
|
|
WVE
Wave Life Sciences Ltd.
WVE-007 includes an siRNA (RNA interference) program, making RNAi therapeutics a core modality for the company.
|
$1.12B |
$7.39
+4.89%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$826.22M |
$4.22
-2.09%
|
|
VIR
Vir Biotechnology, Inc.
Elebsiran is an RNA interference (RNAi) therapeutic, placing Vir in RNAi Therapeutics.
|
$789.05M |
$6.17
+8.63%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT's RNA interference modality (RNAi therapeutics) aligns with a gene-silencing oligonucleotide approach described in the program.
|
$506.25M |
$10.79
-0.46%
|
|
BNTC
Benitec Biopharma Inc.
Benitec's ddRNAi approach centers on RNA interference therapeutics, placing it under RNAi Therapeutics.
|
$348.08M |
$13.11
-1.13%
|
|
SLN
Silence Therapeutics plc
Silence Therapeutics directly develops RNA interference therapeutics (siRNA) as its core product modality.
|
$297.63M |
$6.20
-1.74%
|
|
VYGR
Voyager Therapeutics, Inc.
VY1706 uses siRNA payload delivered via TRACER capsids, mapping to RNAi Therapeutics.
|
$231.86M |
$4.07
-2.75%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$139.01M |
$1.57
+2.27%
|
|
ALEC
Alector, Inc.
ADP064-ABC includes an anti-tau siRNA program, representing RNA interference therapeutics.
|
$125.50M |
$1.28
+3.23%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$33.77M |
$5.14
+2.51%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-KIT is described as a precision antisense therapy, aligning with RNAi therapeutics.
|
$14.39M |
$1.14
+4.61%
|
|
RNAZ
TransCode Therapeutics, Inc.
Company focuses on RNA interference (RNAi) therapeutics, including siRNA/miRNA-targeted programs.
|
$7.20M |
$8.89
+2.89%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is based on RNA interference (siRNA), making RNAi therapeutics a core product/framework.
|
$6.41M |
$1.18
+4.91%
|
|
RGBP
Regen BioPharma, Inc.
DiffronC is described as an in vivo siRNA therapy, placing RGBP in the RNAi Therapeutics space.
|
$287147 |
$0.01
|
Loading company comparison...
Loading industry trends...
Loading research report...
